Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Pergoveris Formulations in Healthy Chinese Women
NCT04899193Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of follitropin alfa and lutropin alfa in infertility (6 arms), sponsored by Merck KGaA. Primary endpoints: Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Sampling Time, Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Infinity and 1 more. Started May 2021; status: completed.
02
Drugs
follitropin alfalutropin alfa
03
Conditions
infertility
Beyond the preview
Go deeper on NCT04899193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899193.